How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Olaparib with bevacizumab is not recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer:

  • has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab

  • is advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) and

  • is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation or genomic instability).

1.2 This recommendation is not intended to affect treatment with olaparib with bevacizumab that was funded with managed access before final guidance was published. If this applies, NHS England and the company have an arrangement to make sure people who started treatment during the period of managed access will continue to have olaparib with bevacizumab until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

This evaluation reviews the evidence for olaparib with bevacizumab for maintenance treatment of HRD-positive, advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (NICE technology appraisal guidance 693). It also reviews new evidence collected as part of the managed access agreement.

New clinical trial evidence shows that people taking olaparib with bevacizumab have more time before their cancer comes back than those having bevacizumab only, and they also live longer. But the economic evidence is very uncertain. When taking into account the committee's preferred assumptions, the cost-effectiveness estimates are not within what NICE considers an acceptable use of NHS resources. So, olaparib is not recommended for routine use in the NHS.